KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.

Roberto Depascale, Raffaele Da Mutten, Julius Lindblom, Nursen Cetrez, Leonardo Palazzo, Luca Iaccarino, Andrea Doria, Dionysis Nikolopoulos, Mariele Gatto, Ioannis Parodis

Rheumatology (Oxford) 64(8) 4650-4658

PMID40244828
PMCIDPMC12316369
DOI10.1093/rheumatology/keaf215
发表日期2025-04-17
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: To determine SLE endotypes according to B cell immunophenotyping and serological profile and assess endotypes' response to belimumab. METHODS: We analysed data from 796 patients with SLE from the phase III trial BLISS-SC. Unsupervised machine learning employing factor analysis of mixed data (FAMD) and subsequent clustering determined endotypes based on B cell immunophenotyping and serological profiles. Cox regression was used to assess belimumab efficacy on inducing lupus low disease activity state (LLDAS) and definitions of remission in SLE (DORIS) remission within clusters. RESULTS: Three endotypes were determined. Compared with each other, cluster 1 (n = 191) displayed higher proportions of CD19+CD24b+CD27+ regulatory B cells (mean ± SD: 35.9%±12.6%), CD19+CD20+CD27+ bulk memory B cells (32.2%±9.9%), CD19+CD20+CD69+ activated B cells (0.2%±0.3%), CD19+CD20-CD138+ long-lived plasma cells (0.7%±1.0%) and CD19+CD38b+CD27b+ SLE-associated plasma cells (6.6%±7.0%). Cluster 2 (n = 366) displayed higher proportions of CD19+CD24bbrightCD38bbrightCD27- transitional B cells (6.3%±9.0%) and CD19+CD20+CD27- naïve B cells (85.4%±7.2%), and lower proportions of CD19+CD20-CD138+ peripheral long-lived plasma cells (0.2%±0.3%) and CD19+CD38b+CD27b+ SLE-associated plasma cells (1.6%±2.0%). Cluster 3 (n = 239) displayed a higher proportion of CD19+CD20+CD138+ short-lived plasma cells (0.1%±0.1%) and higher serological activity, being enriched in anti-double stranded(ds)DNA, anti-ENAs, antiphospholipid antibodies and hypocomplementemia. Use of belimumab was superior to placebo in inducing sustained LLDAS [hazard ratio (HR): 2.22; 95% CI: 1.18-4.17; P = 0.014] and DORIS remission (HR: 3.45; 95% CI: 1.2-9.94; P = 0.022) in cluster 2. CONCLUSION: Three distinct SLE endotypes were identified based on B cell immunophenotyping and serological profiles, showing differential benefit from belimumab therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. t-SNE plot of patient clusters. T-distributed stochastic neighbour embedding (t-SNE) plot depicting the three clusters of patients with SLE identified by an unsupervised analysis using B cell subsets and serology
非 KM Figure
Figure 2Figure 2. B cell maturation pathway and cluster-specific differences. Schematic representation of the B cell maturation pathway, overlaid with the relative percentages of B cell subsets across the three identified patient clusters. The schematic illustrates key maturation stages of B cells, from transitional and naïve B cells to plasmablasts and long-lived plasma cells, highlighting differences in subset abundance across clusters
非 KM Figure
Figure 3Figure 3. Disease activity and organ damage at baseline by clusters. Distribution of scored ( A ) SLEDAI-2K descriptors and ( B ) SDI items grouped by organ system at baseline, stratified by cluster. SLEDAI-2K: SLEDAI 2000; SDI: SLICC/ACR Damage Index
非 KM Figure
Figure 4Figure 4. Trajectories of patient clusters over time. Depicted are SLEDAI-2K score trajectories ( A ), mean prednisone equivalent dose ( B ), LLDAS ( C ) and DORIS remission ( D ) from baseline until the end of the follow-up period across clusters. DORIS: definitions of remission in SLE; LLDAS: lupus low disease activity state; SLEDAI-2K: SLEDAI 2000
非 KM Figure
Figure 5Figure 5. Cox regression applied to the population stratified by clusters. Forest plots illustrating results from Cox regression models investigating clusters in relation to sustained LLDAS ( A ) or sustained DORIS remission ( B ) attainment, adjusting for age, ethnicity, sex and belimumab use, and models investigating belimumab use in relation to sustained LLDAS ( C ) or sustained DORIS remission attainment ( D ) stratified by clusters. DORIS: definitions of remission in SLE; LLDAS: lupus low disease activity state
非 KM Figure